Business
Monument Therapeutics Partnership with FNIH
Cambridge Cognition Holdings plc (AIM: COG) announced that Monument Therapeutics, in which the Group holds a 20% stake valued at £1.8 million, has partnered with the Foundation for the National Institutes of Health (FNIH) for a clinical trial of MT1988, a novel schizophrenia treatment. The trial is part of the FNIH's Accelerating Medicines Partnership® Schizophrenia program, a public-private collaboration with $44 million in committed investment. Cambridge Cognition's technology played a key role in MT1988's early development, and the company also retains future royalty rights. Disclaimer*
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n\n\nAugust 19, 2025\nCambridge Cognition Holdings plc\n(\"Cambridge Cognition\", the \"Company\" or the \"Group\")\n \nCambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia\n \nCambridge UK, August 19, 2025 - Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in development for cognitive impairment associated with schizophrenia, in a proof of principle clinical trial.\n \nSchizophrenia is a serious mental health condition that ranks among the top 15 causes of disability worldwide. Its symptoms include hallucinations, delusions, and cognitive impairments, with many individuals showing early signs during a 'clinical high risk' (CHR) phase, which currently lacks effective treatment options, despite its profound impact on functioning and quality of life.\n \nThe trial will be conducted as part of the FNIH-managed Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program, a public-private collaboration involving the National Institutes of Health (NIH), major pharmaceutical companies, and nonprofit organisations with $44 million of investment committed to date. The initiative aims to accelerate the development of more effective treatments for schizophrenia and related mental health conditions.\n \nCambridge Cognition's proprietary digital cognitive assessment technologies supported the early development of MT1988 and were instrumental in establishing the foundational biomarker strategy for Monument. The Company retains a 20% equity stake, valued at £1.8m, and future royalty rights in Monument Therapeutics, following its spin-out in 2021.\n \nRob Baker, Joint Managing Director and Chief Operating Officer, commented:\n\"Monument's continued progress into patient trials is a significant step in developing precision treatments for brain health. It highlights the value of Cambridge Cognition's digital assessment technology in this field...